Less than half of the children aged 0-14 who have TB are diagnosed – so they never even start treatment.
Academic rigour, journalistic flair
Articles on BCG
Displaying all articles
Manufacturers and health systems have shown that vaccines can be quickly and effectively deployed when accompanied by keen political and financial commitments.
BCG remains the only widely available vaccine for TB. Yet the development of a COVID-19 vaccine over the last year shows that there is capacity to rapidly create new vaccines.
Until vaccines that are capable of protecting all populations against TB are developed, treatment is the best option to preventing infection.
Tuberculosis is a global threat and a public health concern on a scale similar to COVID-19.
Vaccines for other diseases are being examined for their protective effects against coronavirus.
Vaccines have ‘non-specific effects’ that have the potential to save millions of lives.
Top contributors
-
Assistant Professor in Health Economics, London School of Hygiene & Tropical Medicine
-
Clinical Research Fellow in Viral Immunology and Veterinary Surgeon, University of Cambridge
-
Head of the Centre of Excellence for Biomedical TB Research, University of the Witwatersrand
-
Professor of Global Health, Danish Institute for Advanced Study, University of Southern Denmark
-
Senior Research Fellow, James Cook University
-
Lead Senior Scientist, Aurum Institute
-
Assistant Professor, Infectious Disease Epidemiology , London School of Hygiene & Tropical Medicine
-
Socio-behavioural Scientist and Senior Researcher, Stellenbosch University
